Latest Administration News

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

Island Pharmaceuticals has raised $350,000 through an options exercise by substantial shareholder MWP Partners, reinforcing confidence in its antiviral drug development pipeline.

Syntara Limited has received FDA guidance recommending a Phase 2 controlled trial for its lead drug amsulostat in myelofibrosis, setting the stage for a pivotal Phase 3 study. The company is poised to refine its clinical strategy while advancing a diverse pipeline with key data milestones ahead.

Global Health Limited has secured a $186,748 contract to implement its MasterCare+ digital platform at Jarrah House, enhancing alcohol and other drug (AOD) services with tailored technology solutions.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

The Calmer Co. has secured a long-term lease for its Navua facility in Fiji, replacing a planned property purchase and freeing up capital to accelerate its US market expansion.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

Novo Resources Corp. reported key drilling milestones at its Pilbara and New South Wales projects in Q2 2025, alongside a reduced net loss and ongoing liquidity challenges. The company’s exploration momentum continues despite material uncertainty over its going concern status.

Celsius Resources reports steady progress on the MCB Copper-Gold Project feasibility and engineering design, while engaging multiple parties in financing discussions including a new memorandum of understanding with Kiri Industries.

Duxton Farms reported a significant $12.5 million net loss for FY2025, reversing last year’s profit, while declaring an 85% franked dividend of 24 cents per share. The company’s revenue dipped due to property sales and increased expenses tied to a proposed acquisition.